Talk to the Institute
Published mark

MADRIGAL PHARMACEUTICALS, INC.

NASDAQ: MDGL. Canonical company identity and public leadership record.

US

Record source reportedRecord not claimedNo Eval published
Follow companySave PDF
Alpha ID
alpha:company:a2c6f396-355d-4322-a341-7ad70ce14f80
SEC CIK
0001157601
Record version
vpublic-1:d751713988987e9331980363e24189ce:ro-d751713988987e9331980363e24189ce, published Oct 16, 2026
Newest evidence
May 3, 2026
Monitoring
Not yet monitored Details
Integrity
Not yet signed Methodology
CEO
Bill SiboldPresident and Chief Executive Officer
Chair
Not published
Independent
7 / 1010 directors published
Published claims
324 distinct sources
Evidence records
100 pinned
Source conflicts
0None open

Built from 4 distinct sources and 10 evidence records. Every Claim links to where it appears. Where nothing was published, the record states the coverage gap.

CorroboratedSource reportedAlpha inferenceNot disclosed

Public record. Alpha publishes governance facts about this organization from regulatory filings and company statements. Private enterprise overlay data is never projected here. The company can claim the record, correct, or dispute any Claim. How this works

EXECUTIVE APPOINTED

Carole Huntsman executive of MADRIGAL PHARMACEUTICALS, INC., effective 2026-04-28.

EffectiveEffective Apr 28, 2026E4

Monitoring

Continuous

What the published record states about identity, evidence, evaluation, monitoring, authority, and freshness. Watched-source schedules are not published for this record.

  • Identityunclaimed
    Published
  • Evidencesource_reported
    Published
  • Evaluationnot_evaluated
    Published
  • MonitoringNot yet published for this record.
    Not published
  • AuthorityNot yet published for this record.
    Not published
  • Freshnesscurrent
    Published

Leadership

Evidence
RolePersonSinceStatusClaim
Executive Vice President and Chief Commercial OfficerCarole HuntsmanApr 2026currentSource reportedE4
Executive Vice President and Chief Medical OfficerDavid Soergel, M.D.Apr 2026currentSource reportedE6
Executive Vice President and Chief Legal CounselShannon KelleyApr 2026currentSource reportedE8
President and Chief Executive OfficerBill SiboldNot capturedunknownSource reportedE3
Executive Vice President and Chief Medical OfficerDavid SoergelNot capturedunknownSource reportedE5
Executive Vice President and Chief Financial OfficerMardi DierNot capturedunknownSource reportedE7
Executive Vice President and Chief Legal CounselStephen D. KelleyNot capturedunknownSource reportedE9

Board of directors

Evidence

10 directors published. 7 of 10 with a published determination are independent.

DirectorStatusSinceCommitteesClaim
Bill SiboldNot independent2023None publishedSource reportedE2
Fred B. Craves, Ph.D.Independent2016None publishedSource reportedE2
Jacqualyn A. Fouse, Ph.D.Independent2025AuditAudit; Nominating and GovernanceNominating and GovernanceSource reportedE2
James M. DalyIndependent2019AuditAudit; Nominating and GovernanceNominating and GovernanceSource reportedE2
Julian C. BakerIndependent2023Nominating and Governance, chairNominating and Governance · ChairSource reportedE2
Kenneth M. BateIndependent2016Audit, chairAudit · Chair; CompensationCompensationSource reportedE2
Paul A. Friedman, M.D.Not independent2016None publishedSource reportedE2
Raymond Cheong, Ph.D., M.D.Independent2023None publishedSource reportedE2
Rebecca Taub, M.D.Not independent2016None publishedSource reportedE2
Richard S. Levy, M.D.Independent2016None publishedSource reportedE2

Committees and risk ownership

Evidence
CommitteeChairMembersRisks assigned
AuditKenneth M. BateKenneth M. Bate, Jacqualyn A. Fouse, Ph.D., James M. DalyNot described in the published record
Audit · Chair; CompensationNot publishedKenneth M. BateNot described in the published record
Audit; Nominating and GovernanceNot publishedJacqualyn A. Fouse, Ph.D., James M. DalyNot described in the published record
CompensationNot publishedKenneth M. BateNot described in the published record
Nominating and GovernanceJulian C. BakerJulian C. Baker, Jacqualyn A. Fouse, Ph.D., James M. DalyNot described in the published record
Nominating and Governance · ChairNot publishedJulian C. BakerNot described in the published record
Committee RecordAudit: Chair Kenneth M. Bate; Members Kenneth M. Bate (Chair); Jacqualyn A. Fouse, Ph.D.; James M. Daly
Source reportedE10
company:a2c6f396-355d-4322-a341-7ad70ce14f80:committee_record:23
Committee AppointmentKenneth M. Bate: chair, Audit
Source reportedE10
company:a2c6f396-355d-4322-a341-7ad70ce14f80:committee_appointment:24
Committee AppointmentJacqualyn A. Fouse, Ph.D.: member, Audit
Source reportedE10
company:a2c6f396-355d-4322-a341-7ad70ce14f80:committee_appointment:25
Committee AppointmentJames M. Daly: member, Audit
Source reportedE10
company:a2c6f396-355d-4322-a341-7ad70ce14f80:committee_appointment:26
Committee RecordCompensation: Chair not stated; Members Kenneth M. Bate
Source reportedE10
company:a2c6f396-355d-4322-a341-7ad70ce14f80:committee_record:27
Committee AppointmentKenneth M. Bate: member, Compensation
Source reportedE10
company:a2c6f396-355d-4322-a341-7ad70ce14f80:committee_appointment:28
Committee RecordNominating and Governance: Chair Julian C. Baker; Members Julian C. Baker (Chair); Jacqualyn A. Fouse, Ph.D.; James M. Daly
Source reportedE10
company:a2c6f396-355d-4322-a341-7ad70ce14f80:committee_record:29
Committee AppointmentJulian C. Baker: chair, Nominating and Governance
Source reportedE10
company:a2c6f396-355d-4322-a341-7ad70ce14f80:committee_appointment:30
Committee AppointmentJacqualyn A. Fouse, Ph.D.: member, Nominating and Governance
Source reportedE10
company:a2c6f396-355d-4322-a341-7ad70ce14f80:committee_appointment:31
Committee AppointmentJames M. Daly: member, Nominating and Governance
Source reportedE10
company:a2c6f396-355d-4322-a341-7ad70ce14f80:committee_appointment:32

Control and voting power

Evidence

No published claims

Nothing is published for this section yet. A missing Claim is a coverage state, not a negative finding.

Authority to act

Evidence and agent registry

Who can act for the company, and on whose authority. This is what a counterparty's agent checks before it accepts an order, signs, or pays.

Principal executive officerBill Sibold, President and Chief Executive Officer
Source reportedE3
company:a2c6f396-355d-4322-a341-7ad70ce14f80:leadership_role:16
Who can authorize an agentNot assessedNo Alpha inference about signing authority or board-reserved matters is published for this record.
Not assessed
bind
AI agents registered by the companyNot registered in the public RegistryAgent Deployments, Agent Use Cases, Authority Grants, TrustChecks, Action Ledger entries and Governance Receipts live in the private enterprise overlay. They are never projected into the public Registry without explicit cross-plane authorization. Absence here is a plane boundary, not evidence that the enterprise operates no agents.
Agent registry
agents
Delegations publishedNot disclosedBoard and officer delegation resolutions are not public filings and are not published in this record.
Search scope
delegations

Financials and market context

Evidence
Security ListingMDGL (NASDAQ)
Source reportedE1
company:a2c6f396-355d-4322-a341-7ad70ce14f80:security_listing:33
Index membershipsNo current membership is published in Alpha's tracked index universe.This is not evidence that the company is absent from every market index.
None publishedAs of Oct 16, 2026. Rights-filtered public evidence only; no redistribution or model training is granted. Only source-backed memberships with an explicit public redistribution basis are returned.

Governance and policies

Evidence

No published claims

Nothing is published for this section yet. A missing Claim is a coverage state, not a negative finding.

Risk, audit, and cyber

Evidence

No published claims

Nothing is published for this section yet. A missing Claim is a coverage state, not a negative finding.

AI oversight and accountability

Evidence

No published claims

Nothing is published for this section yet. A missing Claim is a coverage state, not a negative finding.

Compensation

Evidence

No published claims

Nothing is published for this section yet. A missing Claim is a coverage state, not a negative finding.

Other published claims

Evidence

Published Claims that belong to no section above. Each keeps its permalink, evidence, and assertion state.

Legal NameMADRIGAL PHARMACEUTICALS, INC.
Source reportedE1
company:a2c6f396-355d-4322-a341-7ad70ce14f80:legal_name:1
Entity StatusPublic listing published
Source reportedE1
company:a2c6f396-355d-4322-a341-7ad70ce14f80:entity_status:3
Published FactHealthcare
Source reportedE1
company:a2c6f396-355d-4322-a341-7ad70ce14f80:published_fact:5

Not yet in this record

Coverage

A gap is a coverage state, not a negative finding. These sections are expected for this entity class and are not yet published.

  • Corporate structureNot reviewed. Parent, subsidiary and predecessor structure explains who is governed.
  • OwnershipNot reviewed. Ownership and voting power determine who can influence the board.
  • FinancialsNot reviewed. Governance-relevant financial context frames capital and audit decisions.
  • CompensationNot reviewed. Pay design shows how incentives are governed.
  • GovernanceNot reviewed. Governing documents and provisions set the rules of the enterprise.
  • Shareholder governanceNot reviewed. Meeting and vote records show shareholder dissent and support.
  • AuditNot reviewed. Auditor, controls and restatements show assurance over reporting.
  • LegalNot reviewed. Material legal and regulatory matters show enforcement exposure.
  • RiskNot reviewed. Risk ownership links the board, committees, executives and controls.
  • CyberNot reviewed. Cyber and data governance is a disclosed oversight domain.
  • AI governanceNot reviewed. AI oversight is a differentiated Alpha governance domain.
  • Markets externalNot reviewed. Auditors, advisors, investors and regulators form the external ecosystem.
  • Absence of a leadership role, committee, or disclosure is not evidence that it does not exist.Absence of a leadership role, committee, or disclosure is not evidence that it does not exist.
  • Only explicitly published canonical company identity and current confirmed public roles are included.Only explicitly published canonical company identity and current confirmed public roles are included.
  • Absence of a board, committee, executive, listing, or claim is not evidence that it does not exist.Absence of a board, committee, executive, listing, or claim is not evidence that it does not exist.
  • Public retrieval does not grant redistribution, model-training, direct-contact, or relationship-pathfinding rights.Public retrieval does not grant redistribution, model-training, direct-contact, or relationship-pathfinding rights.
  • This Company Profile is an identity and evidence record, not an Alpha rating.This Company Profile is an identity and evidence record, not an Alpha rating.

Subject and corrections

Public-role doctrine

This record exists because the company is in the published Registry. The company can claim the record, correct, or dispute any Claim. Corrections are versioned and the original stays in history.

Basis
Published company record built from public sources
Sources
10 evidence records cited. 0 with redistribution rights.
Never published
Private enterprise overlay data: deployments, authority grants, TrustChecks, receipts, telemetry
Record claimed
No
Open disputes
0
Identity ownership
unclaimed
Claiming not yet available

If the company claims the record, its statements appear as their own assertion state and never overwrite the cited evidence.

Evidence

Authority and rights
  1. E1
    Alpha canonical company public projection
    Alpha canonical company public projection. canonical identity. Retrieved Oct 16, 2026. Cited by 5 Claims.
    Open web
    Rights not recorded, link only
    Evidence not pinned
  2. E2
    Madrigal Pharmaceuticals DEF 14A 2025-04-29
    sec proxy. Published Apr 29, 2025. Retrieved May 1, 2026. Cited by 10 Claims.
    Authoritative, regulatory filing
    Rights not recorded, link only
    Evidence not pinned
  3. E3
    MDGL executive roster source
    sec filing. Published May 3, 2026. Retrieved May 3, 2026. Cited by 1 Claim.
    Authority not assessed
    Rights not recorded, link only
    Evidence not pinned
  4. E4
    MDGL DEF 14A executive officers
    sec filing. Published Apr 28, 2026. Retrieved May 16, 2026. Cited by 1 Claim.
    Authoritative, regulatory filing
    Rights not recorded, link only
    Evidence not pinned
  5. E5
    MDGL executive roster source
    sec filing. Published May 3, 2026. Retrieved May 3, 2026. Cited by 1 Claim.
    Authority not assessed
    Rights not recorded, link only
    Evidence not pinned
  6. E6
    MDGL DEF 14A executive officers
    sec filing. Published Apr 28, 2026. Retrieved May 16, 2026. Cited by 1 Claim.
    Authoritative, regulatory filing
    Rights not recorded, link only
    Evidence not pinned
  7. E7
    MDGL executive roster source
    sec filing. Published May 3, 2026. Retrieved May 3, 2026. Cited by 1 Claim.
    Authority not assessed
    Rights not recorded, link only
    Evidence not pinned
  8. E8
    MDGL DEF 14A executive officers
    sec filing. Published Apr 28, 2026. Retrieved May 16, 2026. Cited by 1 Claim.
    Authoritative, regulatory filing
    Rights not recorded, link only
    Evidence not pinned
  9. E9
    MDGL executive roster source
    sec filing. Published May 3, 2026. Retrieved May 3, 2026. Cited by 1 Claim.
    Authority not assessed
    Rights not recorded, link only
    Evidence not pinned
  10. E10
    Audit
    board_seats. board seats. Cited by 10 Claims.
    Authoritative, regulatory filing
    Rights not recorded, link only
    Evidence not pinned

What changed in version public-1:d751713988987e9331980363e24189ce:ro-d751713988987e9331980363e24189ce

vpublic-1:d751713988987e9331980363e24189ce:ro-d751713988987e9331980363e24189ce published Oct 16, 2026
  • Carole Huntsman executive of MADRIGAL PHARMACEUTICALS, INC., effective 2026-04-28.
  • David Soergel, M.D. executive of MADRIGAL PHARMACEUTICALS, INC., effective 2026-04-28.
  • Shannon Kelley executive of MADRIGAL PHARMACEUTICALS, INC., effective 2026-04-28.
  • Jacqualyn A. Fouse, Ph.D. seat on MADRIGAL PHARMACEUTICALS, INC., effective 2025-01-01.
  • Audit; Nominating and Governance committee of MADRIGAL PHARMACEUTICALS, INC., effective 2025-01-01.
  • Jacqualyn A. Fouse, Ph.D. member of Audit; Nominating and Governance, effective 2025-01-01.
  • Bill Sibold seat on MADRIGAL PHARMACEUTICALS, INC., effective 2023-01-01.
  • Julian C. Baker seat on MADRIGAL PHARMACEUTICALS, INC., effective 2023-01-01.
  • Raymond Cheong, Ph.D., M.D. seat on MADRIGAL PHARMACEUTICALS, INC., effective 2023-01-01.
  • Nominating and Governance · Chair committee of MADRIGAL PHARMACEUTICALS, INC., effective 2023-01-01.
  • Julian C. Baker member of Nominating and Governance · Chair, effective 2023-01-01.
  • James M. Daly seat on MADRIGAL PHARMACEUTICALS, INC., effective 2019-01-01.
  • James M. Daly member of Audit; Nominating and Governance, effective 2019-01-01.
  • Fred B. Craves, Ph.D. seat on MADRIGAL PHARMACEUTICALS, INC., effective 2016-01-01.
  • Kenneth M. Bate seat on MADRIGAL PHARMACEUTICALS, INC., effective 2016-01-01.
  • Paul A. Friedman, M.D. seat on MADRIGAL PHARMACEUTICALS, INC., effective 2016-01-01.
  • Rebecca Taub, M.D. seat on MADRIGAL PHARMACEUTICALS, INC., effective 2016-01-01.
  • Richard S. Levy, M.D. seat on MADRIGAL PHARMACEUTICALS, INC., effective 2016-01-01.
  • Audit · Chair; Compensation committee of MADRIGAL PHARMACEUTICALS, INC., effective 2016-01-01.
  • Kenneth M. Bate member of Audit · Chair; Compensation, effective 2016-01-01.
Appearance

Alpha Governance PBC. The Registry records reported facts and Alpha's assessments separately. A missing fact is not evidence that it is false.

Record alpha:company:a2c6f396-355d-4322-a341-7ad70ce14f80, version public-1:d751713988987e9331980363e24189ce:ro-d751713988987e9331980363e24189ce. https://registry.alpha.ac/companies/madrigal-pharmaceuticals-inc

Navigate

On this record

  1. Overview
  2. Monitoring4
  3. Leadership7
  4. Board10
  5. Committees6
  6. Control and voting0
  7. Authority to act4
  8. Financials1
  9. Governance0
  10. Risk0
  11. AI oversight0
  12. Legal0
  13. Compensation0
  14. Other published claims4
  15. Coverage gaps17
  16. Linked people17
  17. Subject and corrections6
  18. Evidence10
  19. Version historyvpublic-1:d751713988987e9331980363e24189ce:ro-d751713988987e9331980363e24189ce

Linked records

Registry

Appearance

esc
  • Actions
    Switch to agent viewJSON, Markdown, MCP
  • Copy Alpha IDalpha:company:a2c6f396-355d-4322-a341-7ad70ce14f80
  • Cite this recordMADRIGAL PHARMACEUTICALS, INC.
  • Copy canonical URLregistry.alpha.ac/companies/madrigal-pharmaceuticals-inc
  • Copy as MarkdownWith assertion states
  • Report an error
  • Theme: System
  • Theme: Light
  • Theme: Dark
  • Records
    MADRIGAL PHARMACEUTICALS, INC.Company
  • Carole HuntsmanPerson
  • David Soergel, M.D.Person
  • Shannon KelleyPerson
  • Bill SiboldPerson
  • David SoergelPerson
  • Mardi DierPerson
  • Stephen D. KelleyPerson
  • Bill SiboldPerson
  • Fred B. Craves, Ph.D.Person
  • Jacqualyn A. Fouse, Ph.D.Person
  • James M. DalyPerson
  • Julian C. BakerPerson
  • Kenneth M. BatePerson
  • Paul A. Friedman, M.D.Person
  • Raymond Cheong, Ph.D., M.D.Person
  • Rebecca Taub, M.D.Person
  • Richard S. Levy, M.D.Person
  • Sections
    OverviewMADRIGAL PHARMACEUTICALS, INC.
  • MonitoringMADRIGAL PHARMACEUTICALS, INC.
  • LeadershipMADRIGAL PHARMACEUTICALS, INC.
  • BoardMADRIGAL PHARMACEUTICALS, INC.
  • CommitteesMADRIGAL PHARMACEUTICALS, INC.
  • Control and votingMADRIGAL PHARMACEUTICALS, INC.
  • Authority to actMADRIGAL PHARMACEUTICALS, INC.
  • FinancialsMADRIGAL PHARMACEUTICALS, INC.
  • GovernanceMADRIGAL PHARMACEUTICALS, INC.
  • RiskMADRIGAL PHARMACEUTICALS, INC.
  • AI oversightMADRIGAL PHARMACEUTICALS, INC.
  • LegalMADRIGAL PHARMACEUTICALS, INC.
  • CompensationMADRIGAL PHARMACEUTICALS, INC.
↑ ↓ move↵ openThis record only

Report an error

Reports attach to the Claim and go to an Alpha analyst through the correction form. Corrections are versioned, and the original stays in history.